-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2

Benzinga·05/08/2026 12:29:19
Listen to the news
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.